Advanced Oncotherapy: LIGHT – regulatory update

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex assembly of its first full energy system, optimising, validating and verifying all aspects of this process. Meanwhile, it is liaising with the relevant regulators as part of the approval process. The FDA has requested some specific beam measurement data, which has added three months to the process but will generate important technical data that differentiates LIGHT and could be used in future marketing.

  • Strategy: Advanced Oncotherapy is developing a compact and modular PT system, which is affordable for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from technology know-how developed by ADAM (CERN spin-off), and relies on a world-class supplier base.
  • Regulatory update: Although the FDA has requested some specific proton beam measurement data that will add up to a maximum of three months to the completion schedule, it highlights the progress that AVO has made with the FDA, and US regulatory approval now appears likely to come ahead of CE marking.
  • First LIGHT: Having been developing this highly technical and complex project for the past six years, the FDA’s request for additional data suggests that the first fully energy LIGHT system will now be completed by the end of 2Q’22. However, the market should be comforted by the progress made towards US approval.
  • Risks: To date, one of the key risks has been funding. However, AVO’s recent largest capital increase, coupled with alternative financing arrangements, have greatly diminished this risk. Regulatory risks have been reduced through ongoing dialogue with the FDA via the modular Q-Submission 510(k) process.
  • Investment summary: After some years in development Advanced Oncotherapy is nearing the finishing line with its first LIGHT system. However, the goal is to have a pipeline of installations to satisfy the pent-up demand and bring down the cost of PT. The current EV is lower than the quantum of investment to get LIGHT to where it is today. Additionally, the NPV of the cashflows from all potential sources of income from AVO’s evolving business model is currently 215p (161p fully diluted).

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    If our articles help you then why not add us as a preferred news source on Google.

    Chesnara: Why Two Deals Are Reshaping Cash Generation and Dividend Confidence (video)

    Chesnara used its latest results discussion to show how recent acquisitions are strengthening the medium-term cash generation outlook. Steve Murray and Tom Howard explained where HSBC Life UK synergies should start to emerge, why the Scottish Widows Europe deal gives the group a useful base in Luxembourg, and how a simplified KPI framework is intended to make the underlying investment case easier to assess.

    Volta Finance: Structural Strengths Shield Against Market Stress (video)

    Volta Finance’s portfolio is built to withstand stress, but markets don’t always price that in. Mark Thomas of Hardman & Co explains how CLO structures, diversification and active management are driving resilience, even as sentiment creates sharp NAV and share price swings.

    Arbuthnot Banking Group: Poised for a Stronger 2026 (video)

    Arbuthnot Banking Group’s 2025 results showed the impact of lower rates, but the interview with Mark Thomas of Harman & Co highlights why the bigger story may be what comes next. Improving credit quality, disciplined specialist lending and a more supportive rate backdrop could help stabilise profits in 2026 and support further progress beyond that.

    ICG Enterprise Trust plc: The Private Equity Play Backing Resilience, Liquidity and Long-Term Growth (video)

    Mark Thomas at Hardman & Co breaks down the key messages from ICG Enterprise Trust plc’s latest shareholder seminar — strong portfolio performance, selective co-investment, progressive dividends and active buybacks. A sharp overview of how ICGT is positioning for long-term growth while keeping risk and liquidity firmly in focus.

    Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

    A 10%+ yield backed by senior secured loans sits at the heart of Real Estate Credit Investments’ strategy. With a strong recovery track record and consistent dividend policy, the company is positioning itself to balance opportunity with risk in a shifting market.

    Accesso Technology Group plc New Payments Strategy Drives Margin Strength and Shareholder Returns (Video)

    Richard Jeans of Hardman & Co outlines why Accesso’s partnership with Adyen could significantly increase wallet share across its global venue base. With 85% repeatable revenues, rising cash EBITDA margins and a £14.5m tender offer set to retire around 12.7% of shares, the group combines operational resilience with capital discipline. Despite this, it trades on around 8.5x 2027 earnings, a discount the analyst believes is unwarranted.

      Search

      Search